company background image
AIM

AIM ImmunoTech NYSEAM:AIM Stock Report

Last Price

US$0.40

Market Cap

US$19.2m

7D

-11.1%

1Y

-69.7%

Updated

02 Dec, 2022

Data

Company Financials +
AIM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AIM Stock Overview

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.

AIM ImmunoTech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AIM ImmunoTech
Historical stock prices
Current Share PriceUS$0.40
52 Week HighUS$1.43
52 Week LowUS$0.39
Beta-0.32
1 Month Change-31.92%
3 Month Change-39.73%
1 Year Change-69.68%
3 Year Change1.32%
5 Year Change-97.49%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Here's Why We're Not Too Worried About AIM ImmunoTech's (NYSEMKT:AIM) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About AIM ImmunoTech's (NYSEMKT:AIM) Cash Burn Situation

Shareholder Returns

AIMUS BiotechsUS Market
7D-11.1%2.7%1.4%
1Y-69.7%-10.3%-16.1%

Return vs Industry: AIM underperformed the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: AIM underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is AIM's price volatile compared to industry and market?
AIM volatility
AIM Average Weekly Movement7.6%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: AIM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AIM's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196622Thomas Equelshttps://www.aimimmuno.com

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

AIM ImmunoTech Inc. Fundamentals Summary

How do AIM ImmunoTech's earnings and revenue compare to its market cap?
AIM fundamental statistics
Market CapUS$19.24m
Earnings (TTM)-US$20.90m
Revenue (TTM)US$135.00k

142.9x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AIM income statement (TTM)
RevenueUS$135.00k
Cost of RevenueUS$176.00k
Gross Profit-US$41.00k
Other ExpensesUS$20.86m
Earnings-US$20.90m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin-30.37%
Net Profit Margin-15,482.96%
Debt/Equity Ratio0%

How did AIM perform over the long term?

See historical performance and comparison